<DOC>
	<DOCNO>NCT01129050</DOCNO>
	<brief_summary>The major purpose study examine effect two source dietary omega-3 fatty acid , give two dos , potential health benefit relate cardiovascular disease prevention . The two source dietary omega-3 fatty acid fish oil , flax seed oil .</brief_summary>
	<brief_title>Effects Omega-3 Fatty Acids Markers Inflammation</brief_title>
	<detailed_description>The major purpose study examine effect two source dietary omega-3 fatty acid , give two dos , potential health benefit relate cardiovascular disease prevention . The two source dietary omega-3 fatty acid fish oil , flax seed oil . Each give low dose could realistically achieve food source alone , high dose could realistically achieve food alone would require supplementation . The outcome study marker inflammation . The subject study elevated risk factor diabetes heart disease meet criterion `` metabolic syndrome '' . These people currently diabetic , diagnose yet heart disease , risk developing disease would likely benefit omega-3 therapy prove effective .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Gender : Both woman men Age : &gt; = 18 year Ethnicity race : All ethnic racial background welcome As defined ATP III National Cholesterol Education program , metabolic syndrome diagnose presence least three follow , measure screen clinic visit : Central obesity measure waist circumference : Men : Greater 40 inch Women : Greater 35 inch Fasting blood triglyceride great equal 150 mg/dL Blood HDL cholesterol : Men : Less 40 mg/dL Women : Less 50 mg/dL Blood pressure great equal 130/85 mmHg Fasting glucose great equal 100 mg/dL Planning available clinic visit bottle pickups 8 week study participation Ability willingness give write informed consent No known active psychiatric illness . Daily intake dietary supplement contain omega3 FAs within past month . Fasting blood glucose &gt; 140 mg/dL Significant liver enzyme abnormality AST ALT 2 time upper limit normal and/or Bilirubin 50 % upper limit normal Renal disease measure baseline : Serum creatinine &gt; 1.30 mg/dL , Calculated creatinine clearance &lt; 71 mL/min Self report personal history : Clotting disorder Clinically significant atherosclerosis ( e.g. , CAD , PAD ) Malignant neoplasm Ongoing infection Inflammatory disease ( e.g. , rheumatoid arthritis ) Subjects currently receive follow medication ( self report ) : AntiInflammatory drug Lipid lower drug include statin Antihypertensive drug Anticoagulant drug Body Mass Index ( BMI ) great equal 40 . Pregnant Lactating Inability communicate effectively study personnel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>